The client was able to gain valuable insights into what drives negotiations for drugs with small target populations. From a pricing perspective, the relevance of orphan designation was deemed to be relatively unimportant compared to actual patient numbers, which were more significant. There were, however, other benefits that orphan drug designation would have afforded the product, such as fast tracking, patent protection and some financial breaks.
